Comparer des méthodes

	EORTC QLQ-LC13 : Qualité de vie dans le cancer du poumon	EORTC QLQ-BR23 : Qualité de vie chez les patientes atteintes de cancer du sein
Domaine	Oncologie	Oncologie
Famille	Process / pipeline	Process / pipeline
Année d'origine	1994	1996
Auteur d'origine	Bergman, B., et al. (EORTC Quality of Life Group)	Sprangers, M. A., et al. (EORTC Quality of Life Group)
Type	Self-report questionnaire	Self-report questionnaire
Source fondatrice	Bergman, B., Aaronson, N. K., Ahmedzai, S., Kaasa, S., & Sullivan, M. (1994). The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer, 30A(5), 635–642.	Sprangers, M. A., Groenvold, M., Arraras, J. I., Franklin, J., te Velde, A., Muller, M., et al. (1996). The European Organization for Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: first results from a three-country field study. J Clin Oncol, 14(10), 2756–2768.
Alias	QLQ-LC13	QLQ-BR23
Apparentées	5	5
Résumé	The EORTC QLQ-LC13 is a 13-item lung-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire. Developed and validated by Bergman et al. in 1994, it measures lung-specific symptoms (dyspnea, cough, hemoptysis, chest pain) and treatment toxicities (sore mouth, dysphagia). It is the standard lung cancer-specific QoL instrument in European and international trials.	The EORTC QLQ-BR23 is a 23-item breast-cancer-specific module designed to complement the 30-item EORTC QLQ-C30 core questionnaire, assessing functional and symptom domains unique to breast cancer. Validated by Sprangers et al. in 1996, it measures body image, sexual function, breast symptoms, and arm symptoms, making it a standard instrument in European and international breast cancer clinical trials and quality-of-life research.